for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Fosun Pharmaceutical (Group)

600196.SS

Latest Trade

53.06CNY

Change

-0.17(-0.32%)

Volume

20,438,377

Today's Range

52.08

 - 

53.78

52 Week Range

23.99

 - 

79.19

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
53.23
Open
53.60
Volume
20,438,377
3M AVG Volume
1,727.44
Today's High
53.78
Today's Low
52.08
52 Week High
79.19
52 Week Low
23.99
Shares Out (MIL)
2,562.90
Market Cap (MIL)
123,361.40
Forward P/E
--
Dividend (Yield %)
0.73

Next Event

Q3 2020 Shanghai Fosun Pharmaceutical Group Co Ltd Earnings Release

Latest Developments

更多

Shanghai Fosun Pharmaceutical Says Unit, Fosun High Tech & Xinghui Anying Entered Partnership Agreement

Shanghai Fosun Pharmaceutical Says Unit Received Letter Of Approval For ORIN1001 Tablet By FDA

Shanghai Fosun Pharmaceutical Group's Unit Got Approval For Clinical Trial For Avatrombopag Maleate Tablet

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.

Industry

Major Drugs

Contact Info

Building A, No. 1289 Yishan Road

SHANGHAI, SHA

200233

China

+86.21.33987870

http://www.fosunpharma.com

Executive Leadership

Qiyu Chen

Chairman of the Board, Executive Director

Fang Yao

Co-Chairman of the Board, Executive Director

Yifang Wu

President, Chief Executive Officer, Executive Director

Xiao Hui Guan

Chief Financial Officer, Senior Vice President

Yu Qing Chen

Senior Vice President

Key Stats

1.92 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

18.5K

2018

24.9K

2019

28.6K

2020(E)

32.7K
EPS (CNY)

2017

1.270

2018

1.070

2019

1.300

2020(E)

1.376
Price To Earnings (TTM)
39.19
Price To Sales (TTM)
4.34
Price To Book (MRQ)
4.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
74.38
LT Debt To Equity (MRQ)
34.90
Return on Investment (TTM)
7.60
Return on Equity (TTM)
4.98

Latest News

Latest News

Fosun unit to begin U.S. trial of COVID-19 antibody treatment soon

China's Shanghai Fosun Pharmaceutical Group said on Thursday an experimental antibody treatment for COVID-19 being developed by its unit had been approved for human testing in the United States and the trial was expected to start soon.

中国复星医药子公司研发新冠肺炎新药,获美国FDA同意开展临床试验

中国复星医药<2169.HK><600196.SS>周四宣布,其控股子公司近日收到美国食品药品监督管理局(FDA)同意旗下一只用于治疗新冠病毒肺炎的新药进行临床试验的函件,并拟于近期具备条件后在美国开始一期临床试验。

中国复星医药子公司研发新冠肺炎新药,获美国FDA同意开展临床试验

中国复星医药周四宣布,其控股子公司近日收到美国食品药品监督管理局(FDA)同意旗下一只用于治疗新冠病毒肺炎的新药进行临床试验的函件,并拟于近期具备条件后在美国开始一期临床试验。

China shares snap rally as experimental vaccines stoke safety concerns

China stocks snapped a three-session rally to close lower on Wednesday, with consumer and healthcare shares leading losses, as experts were concerned over the safety of drugs used in experimental coronavirus vaccines in the country. ** At the close, the Shanghai Composite...

China, HK shares slip as consumer, healthcare drag; experts raise vaccine safety concerns

* WTO finds Washington broke trade rules by putting tariffs on China

UPDATE 1-Germany grants BioNTech, CureVac $745 mln to speed up COVID-19 vaccine work

* German govt grants BioNTech 375 mln EUR, CureVac 252 mln EUR

BioNTech wins $445 mln German grant for COVID-19 vaccine

German biotech firm BioNTech said on Tuesday it had secured almost $450 million in government funding to speed up work on its COVID-19 vaccine candidate and expand its production capacity in Germany.

Shanghai Fosun Pharma, Sinopharm Group sign deal to supply BioNTech coronavirus vaccine candidate

Shanghai Fosun Pharmaceutical has signed a strategic cooperation agreement with Sinopharm Group to supply a coronavirus vaccine candidate developed by German firm BioNTech, it said on Monday.

UPDATE 1-BioNTech, China's Fosun to potentially supply 10 mln doses of COVID-19 vaccine

German drug developer BioNTech SE on Thursday announced a potential deal with Shanghai Fosun Pharmaceutical Group Co Ltd to supply 10 million doses of their COVID-19 vaccine candidate to Hong Kong and Macau.

BioNTech, China's Fosun strikes deal to potentially supply 10 mln doses of COVID-19 vaccine

German drug developer BioNTech SE on Thursday announced a potential deal with Shanghai Fosun Pharmaceutical Group Co Ltd to supply 10 million doses of their COVID-19 vaccine candidate to Hong Kong and Macau.

《股市简讯》A股医药类股大幅下挫,投资者忧虑估值过高

0221GMT - * 中国医药股股价大幅下跌,沪深医药卫生指数一度下滑3.3%--有可能连续第三天收低 * 尽管周一下跌,但该指数今年以来仍上涨逾50%,涨幅名列前茅,因投资者在新冠疫情期间追捧医药股 * 国信证券分析师在报告中称,由于估值过高,医药股面临修正风险 * 复星医药领跌,一度下跌7%,上周五下挫8%;其在香港上市的股票也跌3.1% * 沃森生物、智飞生物、华兰生物、康泰生物和康弘药业 下跌5.5-7%不等 (完) (编译 郑茵 审校 艾茂林)

CORRECTED-UPDATE 2-AstraZeneca in first COVID-19 vaccine deal with Chinese company

* Shenzhen Kangtai to have capacity for at least 100 mln doses by year-end

BioNTech, Fosun launch another COVID-19 vaccine trial

Germany's BioNTech and China's Shanghai Fosun Pharmaceutical on Wednesday announced the start of another COVID-19 vaccine trial in China with a total of 144 participants.

《股市简讯》中国A股医药卫生股上扬,因全球新冠感染病例突破1,500万

0601GMT - * 中国股市医药卫生股上涨,因目前全球新冠病毒感染数量上升 * 沪深300医药卫生指数最高上涨2.6%,今年以来涨幅逾50% * 两地上市的复星医药在沪市领涨,上涨10%至逾两年高点,在香港市场上扬8.7% * 路透统计显示,全球新冠病毒感染病例周三超过1,500万,疫情传播速度加快,而与此同时各国应对方式仍存在分歧 * 渤海证券分析师在报告中表示,在疫情形势不断恶化的不确定性影响下,医药卫生股仍为稀缺资产 * 该券商推荐持有疫苗生产企业和主要医疗设备生产商的股票 * 中美紧张关系升级也提升了医药卫生股这类防御型股票的吸引力...

UPDATE 1-China gives the go-ahead for human trials of BioNTech's COVID vaccine candidate

China has approved an early-stage trial in humans of German firm BioNTech's experimental COVID-19 vaccine, its local partner Shanghai Fosun Pharmaceutical said on Thursday.

China OKs human test for coronavirus vaccine candidate based on BioNTech's technology, says Fosun

China has given the green light to an early-stage human test for a coronavirus vaccine candidate using German firm BioNTech's technology, its local partner said on Thursday.

分析:以“战时速度”全力推进 中国领跑新冠病毒疫苗竞赛

在控制新冠病毒疫情的疫苗研发竞赛中,中国进展神速,科兴控股生物技术<SVA.O>的实验疫苗将在本月稍后将成为中国第二种、全球第三种进入最终测试的疫苗。

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

UPDATE 3-Temasek-led investor group in $250 mln vaccine bet on Germany's BioNTech

* BioNTech, Pfizer developing experimental coronavirus vaccine

UPDATE 1-Germany approves trials of COVID-19 vaccine candidate

Germany gave the green light for human trials of potential coronavirus vaccines developed by German biotech company BioNTech, which is racing teams in Germany, the U.S. and China to develop an agent that will stop the pandemic.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up